NCT05080842: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

NCT05080842
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known symptomatic brain metastases requiring the use of steroids
https://ClinicalTrials.gov/show/NCT05080842

Comments are closed.

Up ↑